UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Clinical and laboratory aspects of platelet transfusion therapy

Authors
Shan Yuan, MD
Dennis Goldfinger, MD
Section Editor
Arthur J Silvergleid, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Hemostasis depends on an adequate number of functional platelets, together with an intact coagulation (clotting factor) system. This topic covers the logistics of platelet use and the indications for platelet transfusion in adults. The approach to the bleeding patient, refractoriness to platelet transfusion, and platelet transfusion in neonates are discussed elsewhere.

(See "Approach to the adult patient with a bleeding diathesis".)

(See "Refractoriness to platelet transfusion therapy".)

(See "Clinical manifestations, evaluation, and management of neonatal thrombocytopenia", section on 'Platelet transfusion'.)

PLATELET COLLECTION

There are two ways that platelets can be collected: by isolation from a unit of donated blood, or by apheresis from a donor in the blood bank.

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jan 2017. | This topic last updated: Mon Sep 19 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21:697.
  2. McCullough J. Overview of platelet transfusion. Semin Hematol 2010; 47:235.
  3. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability--deleterious effect of refrigerated storage. N Engl J Med 1969; 280:1094.
  4. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003; 112:87.
  5. Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science 2003; 301:1531.
  6. Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009; 15:1273.
  7. Kumar A, Mhaskar R, Grossman BJ, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2015; 55:1116.
  8. Nandagopal L, Veeraputhiran M, Jain T, et al. Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion 2016; 56:344.
  9. Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 2011; 51:2269.
  10. Astwood E, Vora A. Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 2011; 152:505.
  11. Vavricka SR, Walter RB, Irani S, et al. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol 2003; 82:570.
  12. van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010; 148:15.
  13. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 2003; 48:S13.
  14. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600.
  15. Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012; 120:748.
  16. Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 2011; 154:425.
  17. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol 2005; 131:588.
  18. Friedmann AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002; 16:34.
  19. Buhrkuhl DC. An update on platelet transfusion in hematooncology supportive care. Transfusion 2010; 50:2266.
  20. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012; :CD004269.
  21. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309.
  22. A Randomised Controlled Trial of Prophylactic Vs No-Prophylactic Platelet Transfusions in Patients with Haematological Malignancies (TOPPS: Trial Of Prophylactic PlateletS) http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=3825 (Accessed on August 21, 2012).
  23. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24:163.
  24. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013; 368:1771.
  25. Simon J. Stanworth, Lise Estcourt, Gillian Powter, et al. The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. American Society of Hematology abstract book 2012; 120:1.
  26. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162:205.
  27. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
  28. Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125:1470.
  29. Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009; 49:873.
  30. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 2008; 48:2128.
  31. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016; 387:2605.
  32. https://clinicaltrials.gov/ct2/results?term=NCT00699621.
  33. Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion 2012; 52:695.
  34. Pandit TN, Sarode R. Blood component support in acquired coagulopathic conditions: is there a method to the madness? Am J Hematol 2012; 87 Suppl 1:S56.
  35. Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:1564.
  36. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007; :172.
  37. Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158:563.
  38. Rock G, Adams GA, Labow RS. The effects of irradiation on platelet function. Transfusion 1988; 28:451.
  39. Przepiorka D, LeParc GF, Stovall MA, et al. Use of irradiated blood components: practice parameter. Am J Clin Pathol 1996; 106:6.
  40. Webb IJ. Transfusion-associated graft-vs-host disease. In: Transfusion reactions, 3rd, Popovsky MA. (Ed), American Association of Blood Banks Press, Bethesda, MD 2007. p.237.
  41. AABB Technical Manual, 17th, Roback JD, Grossman BJ, Harris T, et al. (Eds), American Association of Blood Banks Press, Bethesda, MD 2011. p.237.
  42. King KE, Ness PM. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion 2011; 51:916.
  43. Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy. Transfusion 2004; 44:805.
  44. Goldfinger D, McGinniss MH. Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971; 284:942.
  45. http://obgyan2015.org/wp-content/uploads/2015/11/Rh-negative-and-AntiD.pdf (Accessed on February 24, 2016).
  46. Cid J, Carbassé G, Pereira A, et al. Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients. Transfusion 2011; 51:1163.
  47. Atoyebi W, Mundy N, Croxton T, et al. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 2000; 111:980.
  48. Capocelli KE, Dumont LJ. Novel platelet storage conditions: additive solutions, gas, and cold. Curr Opin Hematol 2014; 21:491.
  49. Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54:1523.
  50. Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108:3210.
  51. de Wildt-Eggen J, Nauta S, Schrijver JG, et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000; 40:398.
  52. Heddle NM, Arnold DM, Boye D, et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:1447.
  53. Daurat A, Roger C, Gris J, et al. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data. Transfusion 2016; 56:1295.
  54. Center for Biologics Evaluation and Research, Food and Drug Administration. Workshop on bacterial contamination of platelets. Bethesda, MD: Food and Drug Administration, Center for Biologics Evaluation and Research; 1999. www.fda.gov/cber/minutes/workshop-min.htm (Accessed on November 15, 2012).
  55. Centers for Disease Control and Prevention (CDC). Fatal bacterial infections associated with platelet transfusions--United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:168.
  56. Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013; 53:1603.
  57. Jacobs MR, Smith D, Heaton WA, et al. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51:2573.
  58. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738.
  59. Kim HW, Greenburg AG. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others. Artif Cells Blood Substit Immobil Biotechnol 2006; 34:537.
  60. Okamura Y, Katsuno S, Suzuki H, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 2010; 148:373.